All In Biotech

Drug Trial Radar · NCT04520750

VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita

VALO-2: A Multicenter, Phase 3b, Open-Label Treatment Extension Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita

Last checked: Nov 19, 2026Latest source record: Aug 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

36

Actual

Start

Sep 1, 2020

Primary completion

Jun 30, 2021

Study completion Dec 15, 2022

Sponsor

Lead sponsor
Palvella Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Aug 20, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

VALO-2 is a multicenter, open-label extension (OLE) study enrolling patients with genotyped keratin mutations KRT6A, KRT6B and KRT16 who were previously treated with investigational PTX-022 during the VALO study. The purpose of the OLE study is to investigate long term exposure to investigational PTX-022 and evaluate safety and efficacy data. A sub-study is included to evaluate safety and efficacy of patients with genotyped keratin mutations of KRT6C and KRT17 not previously treated with investigational PTX-022.

Conditions

  • Pachyonychia Congenita

Interventions

  • PTX-022Drug

    Safety and Efficacy of PTX-022 in the Treatment of Adults with Pachyonychia Congenita

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse EventsTime frame: 18 Months
  2. Changes in vital sign measurements from baselineTime frame: 18 months
  3. Changes in weight measurements from baselineTime frame: 18 months
  4. Changes in clinical laboratory measurements from baselineTime frame: 18 months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Arizona Research Center

    Phoenix, Arizona

  • Stanford University

    Palo Alto, California

  • Minnesota Clinical Study Center

    Fridley, Minnesota

  • University of Utah

    Murray, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.